Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38,735Revenue $M15,259Net Margin (%)11.9Z-Score3.2
Enterprise Value $M44,484EPS $3.7Operating Margin %15.7F-Score5
P/E(ttm))20.1Cash Flow Per Share $5.6Pre-tax Margin (%)15.2Higher ROA y-yN
Price/Book4.510-y EBITDA Growth Rate %12.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %6.5Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %0.9ROA % (ttm)7.7Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)23.8Less Shares Outstanding y-yY
Payout Ratio %56.0Shares Outstanding M543ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 71.46-3%Add 90872.4%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 71.46-3%New holding, 37150 sh.37,150
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 71.46-3%Reduce -30.98%123,976
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 71.46-3%Sold Out0
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 71.46-3%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 71.46-3%Reduce -50%3,725
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 71.46-3%Sold Out0
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 71.464%New holding, 204560 sh.204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 71.464%Add 13.41%179,629
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 71.464%New holding, 2453 sh.2,453
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 71.464%Reduce -85.53%1,100
BAXJohn Hussman 2014-03-31 Reduce-0.49%$66.49 - $72.85
($68.75)
$ 71.464%Reduce -93.07%7,450
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 71.464%Reduce -77.96%531,100
BAXRay Dalio 2014-03-31 Reduce-0.07%$66.49 - $72.85
($68.77)
$ 71.464%Reduce -67%62,263
BAXScott Black 2013-12-31 Add1.06%$63.89 - $69.47
($66.75)
$ 71.467%Add 776.11%158,392
BAXJohn Hussman 2013-12-31 Reduce-0.54%$63.89 - $69.47
($66.75)
$ 71.467%Reduce -58.26%107,450
BAXJean-Marie Eveillard 2013-12-31 Reduce-0.26%$63.89 - $69.47
($66.75)
$ 71.467%Reduce -99.44%7,600
BAXJames Barrow 2013-12-31 Sold Out -0.22%$63.89 - $69.47
($66.75)
$ 71.467%Sold Out0
BAXVanguard Health Care Fund 2013-12-31 Reduce-0.17%$63.89 - $69.47
($66.75)
$ 71.467%Reduce -24.2%2,410,000
BAXRay Dalio 2013-12-31 Reduce-0.03%$63.89 - $69.47
($66.75)
$ 71.467%Reduce -24.85%188,663
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAX Jean-Marie Eveillard 2014-06-301,000,6960.180.18+90872.4%
BAX John Keeley 2014-06-3037,1500.010.05New Buy
BAX Mario Gabelli 2014-06-30243,4000.040.09+7.94%
BAX Charles Brandes 2014-06-30209,9070.040.18+2.61%
BAX Tweedy Browne 2014-06-302,592,1550.484-0.37%
BAX Dodge & Cox 2014-06-303,38200-0.65%
BAX Scott Black 2014-06-30123,9760.021.3-30.98%
BAX John Hussman 2014-06-303,72500.02-50%
BAX Ray Dalio 2014-06-305,76300-90.74%
BAX David Dreman 2014-06-30000Sold Out
BAX Vanguard Health Care Fund 2014-06-30000Sold Out
BAX Meridian Funds 2013-06-308,60000.02
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-4.06view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-6.65view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-6.46view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-5.45view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-3.43view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-4.54view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-0.81view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-1.72view
Bufalino Sebastian JCorporate Vice President 2014-03-27Sell21,600$75.1-4.31view
Shapazian Carole JDirector 2013-09-12Sell1,941$71.580.39view

Press Releases about BAX :

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Abbott: A Brighter Future Aug 28 2014 
Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
Why I Bought Baxter International Jun 19 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
Two Stocks On My Watch List For June 2014 May 29 2014 
Companies That Are Raising Dividends May 16 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
4 Top Stocks in the Medical Device Sector Apr 11 2014 

More From Our Partners
BioMed Leases Space to Baxter for R&D Center in MA - Analyst Blog Sep 30 2014 - ZACKS

More From Other Websites
BioMed Leases Space to Baxter for R&D Center in MA Sep 30 2014
Baxter plans to open R&D center in Mass. for Baxalta spinoff Sep 29 2014
Baxter to Form New Global Innovation and R&D Center near Boston for Its Biopharmaceuticals Business Sep 29 2014
Kamada extends emphysema drug deal with Baxter through 2017 Sep 29 2014
[video] Shah Favors Big Pharmaceuticals Focused on Obesity Sep 26 2014
PharmaEngine and Merrimack Amend MM-398 License Agreement Sep 26 2014
Baxter International Third Quarter 2014 Financial Results Conference Call Sep 25 2014
Baxter and Merrimack Collaborate on Drug Development Sep 25 2014
Stocks Gain While Dollar Reaches Highest Level Since 2010 Sep 24 2014
Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today Sep 24 2014
Merrimack, Baxter to collaborate on cancer drug Sep 24 2014
Merrimack, Baxter to collaborate on cancer drug Sep 24 2014
US STOCKS-Wall St set for modest gains at open after three-day slump Sep 24 2014
Merrimack Does Well to License Marginal Cancer Drug to Baxter Sep 24 2014
Baxter to market Merrimack's cancer drug outside U.S. Sep 24 2014
Merrimack Pharma shares surge on licensing pact with Baxter Sep 24 2014
[$$] Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug Sep 24 2014
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and... Sep 24 2014
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and... Sep 24 2014
BAX, COV And MDT, Pushing Health Services Industry Downward Sep 17 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 3 months ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK